Search research articles
Contact Us
Filters
Showing results (111-120 of 234) with videos related to
Page
of 24
Sort By:
The Oncologist
|
May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer
Julie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
Emmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
European Urology
|
June 28, 2014
Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer
Evan Y Yu, Robert H Getzenberg, Christopher C Coss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2026
131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study
Evan Y Yu, Vivek Narayan, Giuseppe Esposito, et al.
Nature Medicine
|
June 1, 2024
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Thomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, et al.
The Canadian Journal of Urology
|
October 13, 2020
Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV
E David Crawford, Gerald Andriole, Stephen J Freedland, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
Urologic Oncology
|
August 26, 2022
Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events
Anthea Phuong, J Peter Marquardt, Ryan O'Malley, et al.
Clinical Genitourinary Cancer
|
October 8, 2018
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Andrea Necchi, Gregory R Pond, Marco Moschini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Daniel P Petrylak, Bernhard J Eigl, Saby George, et al.
Page
of 24
Search research articles
Search
Showing results (111-120 of 234) with videos related to
Sort By:
Page
of 24
The Oncologist
|
May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer
Julie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
Emmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
European Urology
|
June 28, 2014
Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer
Evan Y Yu, Robert H Getzenberg, Christopher C Coss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2026
131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study
Evan Y Yu, Vivek Narayan, Giuseppe Esposito, et al.
Nature Medicine
|
June 1, 2024
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial
Thomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto, et al.
The Canadian Journal of Urology
|
October 13, 2020
Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV
E David Crawford, Gerald Andriole, Stephen J Freedland, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617
Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
Urologic Oncology
|
August 26, 2022
Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events
Anthea Phuong, J Peter Marquardt, Ryan O'Malley, et al.
Clinical Genitourinary Cancer
|
October 8, 2018
Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Andrea Necchi, Gregory R Pond, Marco Moschini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Daniel P Petrylak, Bernhard J Eigl, Saby George, et al.
Page
of 24